TCI GENE Inc. (6879) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of TCI GENE Inc. stock TWD 26.38, price TWD 35.75, that is 26.2% below the price, quality 72 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
11‑month range 32.60 TWD – 41.00 TWD · fair‑value band 25.87 TWD – 33.12 TWD · the 35.75 TWD price screens above the 26.38 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow TCI GENE in your weekly email
Every Wednesday you see whether TCI GENE is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
TCI GENE Inc., together with its subsidiaries, provides genetic testing and assessment services in Taiwan and Mainland China. It operates through Inspection and Consumable Products segments.
Show moreShow less
The company offers memory, anti-aging, health management, child growth and development, nutritional metabolism and absorption, OB weight management, and SC skin management genetic testing; gut microbiota testing; and LDT cardiovascular drug gene testing services.
It also provides precision prediction and personalized health management plans; and adipose-derived mesenchymal stem cells, natural killer immune cells, and immune cell storage programs.
In addition, the company manufactures and sells testing reagents, health food, and beauty products; and health and nutritional supplements. TCI GENE Inc. was founded in 2011 and is based in Taipei, Taiwan.
Stock analysis
TCI GENE Inc. (6879) currently trades at 35.75 TWD, while our model-based Fair Value estimate is 26.38 TWD, 26% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 64.58 TWD per share, and 11 of the 24 models we run sit above the 35.75 TWD price.
Bear case: the Earnings-Based group reads lowest at 14.28 TWD, and 13 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: 25.87 TWD (bear) to 33.12 TWD (bull), the price of 35.75 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 72/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
TCI GENE Inc. reported revenue of 274M TWD in FY2025 versus 432M TWD in FY2021, a compound −10.8%/yr. Reported net income was 40.6M TWD in FY2025, compounding −18.6%/yr from FY2021.
Key figures
Market cap 946M TWD (≈ $28.8M) Micro · P/E ratio 18.8 · P/S ratio 3.65 · EPS (TTM) 1.90 TWD · Dividend yield 5.6% · Net margin 20.1% · Return on equity 5.6% · Return on assets (EBIT) 7.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −26%, 6879 screens richer than that median.
Fair Value models
Bear25.87 TWDFair Value 26.38 TWDBull33.12 TWD
Price 35.75 TWD · Downside -26.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1.63 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−21.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.6%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−9.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−15.2%
Dividend (yield on the price)5.6%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.26% → 7%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−18.3%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about −19.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score72 · Top 25%
Fair Value upside−23.9% · Above median
Profitability
Return on equity (12 months)5.6% · Top 25%
Return on assets4.0% · Top 25%
Net margin (12 months)20.1% · Above median
Operating margin (12 months)14.6% · Above median
Growth and dividend
Revenue growth (quarter YoY)−15.7% · Bottom 25%
Dividend yield (12 months)5.6% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "TCI GENE Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6879
Frequently asked questions
Is TCI GENE Inc. (6879) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 26.38 TWD versus a price of 35.75 TWD, about 26% lower (overvalued).
What is the fair value of 6879?
Our model-based fair value for TCI GENE Inc. is 26.38 TWD (as of Nov 4, 2026), built from audited fundamentals. The current price: 35.75 TWD.
What is the quality score of 6879?
TCI GENE Inc. has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TCI GENE Inc. (6879)?
Our model-based price target is the fair value of 26.38 TWD (as of Nov 4, 2026) from 24 valuation models. Cautious scenario 25.87 TWD, optimistic scenario 33.12 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the TCI GENE Inc. stock forecast for 2026?
Our models put fair value at 26.38 TWD, about 26% lower versus a price of 35.75 TWD (overvalued). Cautious scenario 25.87 TWD, optimistic scenario 33.12 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of TCI GENE Inc. (6879)?
TCI GENE Inc. reported trailing-twelve-month revenue of about 251M TWD (latest available figure, as of Nov 4, 2026).
Does TCI GENE Inc. pay a dividend?
TCI GENE Inc. currently shows a dividend yield of 5.56% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of TCI GENE Inc. (6879)?
TCI GENE Inc. has a dividend yield of 5.6%.
What growth is priced into TCI GENE Inc. (6879)?
For today's price to be fair in a discounted-cash-flow model, TCI GENE Inc. would have to grow free cash flow by -18.3 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew -10.8 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of 6879 use?
Our models discount TCI GENE Inc. at 9.0 %: a base by market capitalisation (nano), damped by beta 0.28, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For TCI GENE Inc. that is -18.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has TCI GENE Inc. (6879) delivered so far?
Over the past 4 years revenue at TCI GENE Inc. grew -10.8 % a year. The price currently implies free-cash-flow growth of -18.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of TCI GENE Inc. (6879) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into TCI GENE Inc. (-18.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of TCI GENE Inc. (6879)?
The free-cash-flow yield on the price is 15.95 %: that much free cash flow TCI GENE Inc. produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of TCI GENE Inc. (6879)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TCI GENE Inc. it is 26.38 TWD per share (as of Nov 4, 2026), against a price of 35.75 TWD. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is TCI GENE Inc. stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 6879 trades above its calculated fair value: price 35.75 TWD, fair value 26.38 TWD, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6879?
No. The price is what the market pays today (35.75 TWD); the fair value is what the company's own numbers justify (26.38 TWD). For TCI GENE Inc. the two are 9.37 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is TCI GENE Inc. worth?
The market values TCI GENE Inc. at about 946M TWD (market capitalisation, as of Nov 4, 2026). Per share that is 35.75 TWD; our models calculate a fair value of 26.38 TWD per share.
What do the bullish and bearish scenarios say about 6879?
Our models span a range for TCI GENE Inc.: cautious scenario 25.87 TWD, base 26.38 TWD, optimistic 33.12 TWD per share (as of Nov 4, 2026, price 35.75 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6879?
TCI GENE Inc. trades at a price-to-earnings ratio of 18.8 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 26.38 TWD is built from several models across several years. Other multiples: P/B 1.0, P/S 3.6, EV/EBITDA 19.8.
How solid is the balance sheet of TCI GENE Inc. (6879)?
Balance-sheet figures for TCI GENE Inc. (as of Nov 4, 2026): return on equity 5.6%. They feed the Quality Score of 72/100, which measures business quality independently of the share price.
How far is 6879 from its 52-week high?
TCI GENE Inc. trades at 35.75 TWD, about 13% below its 52-week high of 41.00 TWD and 10% above the low of 32.60 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 26.38 TWD is for.
Which stocks are comparable to TCI GENE Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TCI GENE Inc. stock attractive at the current price?
The data as of Nov 4, 2026: price 35.75 TWD, calculated fair value 26.38 TWD (−26%), Quality Score 72/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6879 calculated?
We run TCI GENE Inc. through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 26.38 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. TCI GENE Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of TCI GENE Inc. (6879)?
The closing price on Nov 9, 2026 was 35.75 TWD. Our model-based fair value is 26.38 TWD, about 26% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with TCI GENE Inc. right now?
The price sits above even our optimistic bull case (33.12 TWD). The favourable scenario is already priced in. Solid but not exceptional quality (72/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of TCI GENE Inc.
How large is the market capitalisation of TCI GENE Inc. (6879)?
The market capitalisation of TCI GENE Inc. is 946M TWD (≈ $28.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of TCI GENE Inc. (6879)?
The price-to-sales ratio of TCI GENE Inc. is 3.65 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of TCI GENE Inc. (6879)?
Earnings per share at TCI GENE Inc. are 1.90 TWD (price ÷ EPS = P/E 18.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of TCI GENE Inc. (6879)?
The dividend yield of TCI GENE Inc. is 5.6% (payout 105%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of TCI GENE Inc. (6879)?
The net margin of TCI GENE Inc. is 20.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of TCI GENE Inc. (6879)?
The return on equity (ROE) of TCI GENE Inc. is 5.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of TCI GENE Inc. (6879)?
On an EBIT basis the return on assets of TCI GENE Inc. is 7.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of TCI GENE Inc. (6879)?
The operating margin of TCI GENE Inc. is 14.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at TCI GENE Inc. (6879)?
Revenue at TCI GENE Inc. is growing −15.7% versus a year earlier (3y avg −13.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at TCI GENE Inc. (6879)?
Earnings per share at TCI GENE Inc. are growing +325% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch TCI GENE Inc. in the live analysis
One click puts TCI GENE Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 4, 2026